Merus NV
NASDAQ:MRUS

Watchlist Manager
Merus NV Logo
Merus NV
NASDAQ:MRUS
Watchlist
Price: 90 USD -7.14% Market Closed
Market Cap: 6.8B USD

Operating Margin
Merus NV

-655.4%
Current
-493%
Average
-4.7%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-655.4%
=
Operating Profit
-371m
/
Revenue
56.6m

Operating Margin Across Competitors

No Stocks Found

Merus NV
Glance View

Merus NV, a Dutch biotechnology company, stands at the forefront of innovative cancer therapies, channeling its efforts into research and development of multispecific antibodies. Its proprietary technology platform, Biclonics®, ingeniously harnesses the power of full-length human antibodies to target multiple pathways in the treatment of cancer. Each Biclonics® candidate is designed to bind simultaneously to more than one target, acting like a precision-guided missile that seeks out cancer cells and disrupts the signaling processes that allow tumors to grow and spread. This cutting-edge approach aims to overcome the limitations of traditional monoclonal antibodies and offers promising new avenues for tackling cancer’s incessant complexity. The company's business model is built upon a robust pipeline strategy, where promising drug candidates are both developed in-house and guided through strategic collaborations with larger pharmaceutical entities. These collaborations often involve licensing agreements that provide Merus NV with milestone payments and royalties, creating a significant revenue stream. As these partnerships amplify its reach and bolster its financial health, Merus maintains a primary focus on advancing its leading drug candidates through clinical trials. By aligning groundbreaking science with strategic collaborations, Merus NV works to convert its innovations into viable products that can potentially transform the landscape of cancer treatment, striving to turn scientific potential into practical solutions and profitable outcomes.

MRUS Intrinsic Value
HIDDEN
Show
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-655.4%
=
Operating Profit
-371m
/
Revenue
56.6m
What is the Operating Margin of Merus NV?

Based on Merus NV's most recent financial statements, the company has Operating Margin of -655.4%.

Back to Top